NASDAQ:XOMA

XOMA (XOMA) Stock Forecast, Price & News

$15.56

-0.17 (-1.08%)

(As of 01:48 PM ET)

Compare

Today's Range: $15.53
▼
$15.90
50-Day Range: $14.02
▼
$17.71
52-Week Range: $13.68
▼
$26.00

Volume: 2,601 shs
Average Volume: 35,150 shs
Market Capitalization: $178.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $74.00

XOMA MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 368.4% Upside
$74.00 Price Target
Short Interest: Bearish
5.88% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.22
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.50) to ($0.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

862nd out of 966 stocks

Pharmaceutical Preparations Industry

413th out of 448 stocks

3.5

Analyst's Opinion

Consensus Rating
XOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $74.00, XOMA has a forecasted upside of 368.4% from its current price of $15.80.
Amount of Analyst Coverage
XOMA has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
5.88% of the outstanding shares of XOMA have been sold short.
Short Interest Ratio / Days to Cover
XOMA has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.
Change versus previous month
Short interest in XOMA has recently increased by 8.63%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
XOMA does not currently pay a dividend.
Dividend Growth
XOMA does not have a long track record of dividend growth.

3.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
XOMA has received a 26.63% net impact score from Upright. The largest positive contribution comes from its "Distributing knowledge" impact, which is false driven by its "Mutual funds investing in the pharmaceuticals industry" product. See details.
Environmental Sustainability
The Environmental Impact score for XOMA is -0.22.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for XOMA this week, compared to 1 article on an average week.
MarketBeat Follows
Only 2 people have added XOMA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, XOMA insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.20% of the stock of XOMA is held by insiders.
Percentage Held by Institutions
65.35% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for XOMA are expected to grow in the coming year, from ($2.50) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of XOMA is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of XOMA is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
XOMA has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About XOMA (NASDAQ:XOMA) Stock

XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets. The company was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Price History

30 days | 90 days | 365 days | Advanced Chart

XOMA Stock News Headlines

September 15, 2023 | americanbankingnews.com

XOMA (NASDAQ:XOMA) Rating Reiterated by HC Wainwright

September 13, 2023 | nasdaq.com

HC Wainwright & Co. Reiterates XOMA (XOMA) Buy Recommendation

September 22, 2023 | UNKNOWN (Ad)

Bringing Space Down to Earth

Cutting edge, AI-powered, Space-based Earth-observation solutions

September 6, 2023 | finance.yahoo.com

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023 | msn.com

XOMA (XOMA) Price Target Increased by 18.40% to 75.48

August 9, 2023 | msn.com

HC Wainwright & Co. Maintains XOMA (XOMA) Buy Recommendation

August 8, 2023 | finanznachrichten.de

XOMA Corporation: XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

August 8, 2023 | msn.com

XOMA GAAP EPS of -$0.59, revenue of $1.7M

September 22, 2023 | UNKNOWN (Ad)

Bringing Space Down to Earth

Cutting edge, AI-powered, Space-based Earth-observation solutions

July 7, 2023 | finanznachrichten.de

Simple Spirits Company LLC: Simple Spirits Shines at the San Francisco World Spirits Competition

June 28, 2023 | benzinga.com

Tom Burns Elected to the Acorda Therapeutics Board of Directors

June 22, 2023 | msn.com

Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst

June 22, 2023 | seekingalpha.com

XOMA acquires drug rights from LadRx for $5M

June 22, 2023 | finance.yahoo.com

LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

June 22, 2023 | finance.yahoo.com

XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset

June 15, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Xoma (XOMA)

June 15, 2023 | benzinga.com

HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $69 Price Target

May 24, 2023 | msn.com

XOMA's Return On Capital Employed Insights

May 23, 2023 | seekingalpha.com

XOMAP XOMA Corporation 8.625% CUM PERP PFD SER A

May 16, 2023 | finance.yahoo.com

Shareholders in XOMA (NASDAQ:XOMA) are in the red if they invested five years ago

May 11, 2023 | finance.yahoo.com

Acorda Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023 | msn.com

XOMA: Q1 Earnings Insights

May 10, 2023 | msn.com

XOMA GAAP EPS of -$0.98, revenue of $0.44M

May 9, 2023 | finance.yahoo.com

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy

April 26, 2023 | finance.yahoo.com

XOMA to Present at H.C. Wainwright BioConnect Investor Conference

March 30, 2023 | finance.yahoo.com

XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

March 10, 2023 | finance.yahoo.com

XOMA Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line

See More Headlines

Receive XOMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA Company Calendar

Last Earnings: 8/08/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:XOMA
CUSIP: 98419J10
CIK: 791908
Web: www.xoma.com
Phone: (510) 204-7200
Fax: 510-649-7571
Employees: 11
Year Founded: 1981

Price Target and Rating

Average Stock Price Forecast: $74.00
High Stock Price Forecast: $74.00
Low Stock Price Forecast: $74.00
Forecasted Upside/Downside: +375.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,100,000.00
Net Margins: -663.07%
Pretax Margin: -629.51%
Return on Equity: -22.33%
Return on Assets: -19.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.42
Quick Ratio: 5.42

Sales & Book Value

Annual Sales: $6.03 million
Price / Sales: 29.60
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.83 per share
Price / Book: 1.44

Miscellaneous

Outstanding Shares: 11,470,000
Free Float: 10,876,000
Market Cap: $178.47 million
Optionable: Not Optionable
Beta: 0.87

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Thomas M. Burns (Age 49)
Sr. VP of Fin. & CFO
Comp: $538.45k

Mr. Owen P. Hughes Jr. (Age 48)
Exec. Chairman & Interim CEO

Mr. Brad Sitko
Chief Investment Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XOMA Stock - Frequently Asked Questions

Should I buy or sell XOMA stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XOMA shares.
View XOMA analyst ratings or view top-rated stocks.
What is XOMA's stock price forecast for 2023?: 1 Wall Street analysts have issued 1-year target prices for XOMA's stock. Their XOMA share price forecasts range from $74.00 to $74.00. On average, they predict the company's stock price to reach $74.00 in the next year. This suggests a possible upside of 375.6% from the stock's current price.
View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts.
How have XOMA shares performed in 2023?: XOMA's stock was trading at $18.40 on January 1st, 2023. Since then, XOMA stock has decreased by 15.4% and is now trading at $15.56.
View the best growth stocks for 2023 here.
When is XOMA's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our XOMA earnings forecast.
How were XOMA's earnings last quarter?: XOMA Co. (NASDAQ:XOMA) posted its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.07. The biotechnology company had revenue of $1.66 million for the quarter, compared to analysts' expectations of $1.70 million. XOMA had a negative trailing twelve-month return on equity of 22.33% and a negative net margin of 663.07%.
What is John Varian's approval rating as XOMA's CEO?: 11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees.

What other stocks do shareholders of XOMA own?: Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO).
What is XOMA's stock symbol?: XOMA trades on the NASDAQ under the ticker symbol "XOMA."
Who are XOMA's major shareholders?: XOMA's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (3.74%), Stonepine Capital Management LLC (3.05%), Stonepine Capital Management LLC (3.05%), Geode Capital Management LLC (1.34%), State Street Corp (1.11%) and HighVista Strategies LLC (1.04%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Matthew D Perry, Owen Hughes, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends.
How do I buy shares of XOMA?: Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is XOMA's stock price today?: One share of XOMA stock can currently be purchased for approximately $15.56.
How much money does XOMA make?: XOMA (NASDAQ:XOMA) has a market capitalization of $178.47 million and generates $6.03 million in revenue each year. The biotechnology company earns $-17,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis.
How can I contact XOMA?: XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The official website for the company is www.xoma.com. The biotechnology company can be reached via phone at (510) 204-7200, via email at jsnowden@oratoriumgroup.com, or via fax at 510-649-7571.

This page (NASDAQ:XOMA) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial